Blog
About

5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Subconjunctival mitomycin C as adjunctive therapy before pterygium excision.

      Ophthalmology

      Treatment Outcome, Adult, Safety, Recurrence, surgery, pathology, drug therapy, Pterygium, Prospective Studies, Preoperative Care, therapeutic use, Mitomycin, Male, Injections, Intralesional, Humans, Follow-Up Studies, Female, Conjunctiva, Chemotherapy, Adjuvant, Antibiotics, Antineoplastic

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery. Prospective noncomparative case series. Thirty-six eyes of 36 patients. Thirty-six eyes of 36 patients prospectively received 0.1 ml of 0.15 mg/ml mitomycin C subconjunctivally injected into the head of the pterygium 1 month before bare sclera surgical excision. Recurrence of pterygia. The pterygia resolved in 34 (94%) of 36 eyes, with a recurrence rate of 6% over a mean follow-up of 24.4 months. No wound-healing complication developed in any patient. Subconjunctival mitomycin C is an effective treatment before pterygium excision. Subconjunctival injection allows exact titration of mitomycin C delivery to the activated fibroblasts and minimizes epithelial toxicity.

          Related collections

          Author and article information

          Journal
          12750105
          10.1016/S0161-6420(03)00091-5

          Comments

          Comment on this article